| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis (NCT02065154) | University of Alabama at Birmingham | 2013-08-27 |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy (NCT01956799) | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 2013-05-01 |
| Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (NCT01712308) | M.D. Anderson Cancer Center | 2013-02-21 |
| Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis (NCT01758588) | Weill Medical College of Cornell University | 2013-01-01 |
| Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (NCT01693601) | John Mascarenhas | 2013-01-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis (NCT01730248) | Novartis Pharmaceuticals | 2012-12-18 |
| JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis (NCT01795677) | French Innovative Leukemia Organisation | 2012-12-01 |
| Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (NCT01692366) | Bristol-Myers Squibb | 2012-11-01 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis (NCT05410470) | Qilu Hospital of Shandong University | 2012-08-01 |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (NCT01520220) | Eli Lilly and Company | 2012-06-11 |
| INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (NCT01493414) | Novartis Pharmaceuticals | 2011-08-16 |
| Clinical and Pathophysiological Investigations Into Erdheim Chester Disease (NCT01417520) | National Human Genome Research Institute (NHGRI) | 2011-08-01 |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (NCT01398462) | JW Pharmaceutical | 2011-07-01 |
| Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) (NCT01317875) | Incyte Corporation | 2011-03-31 |
| Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients (NCT01340651) | Incyte Corporation | 2011-03-01 |
| Anti-TGF-beta Therapy in Patients With Myelofibrosis (NCT01291784) | John Mascarenhas | 2011-02-01 |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (NCT01300611) | Tarix Pharmaceuticals | 2011-01-01 |
| Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza (NCT01290302) | American Regent, Inc. | 2010-11-22 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States (NCT00997386) | University of Arizona | 2009-09-01 |
| Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial (NCT00934544) | Novartis Pharmaceuticals | 2009-07-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies (NCT00719836) | S*BIO | 2008-08-01 |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis (NCT00745550) | S*BIO | 2008-08-01 |
| Bone Marrow Transplant Chart Review for RIC (NCT00723333) | University of Utah | 2008-05-01 |
| CEP-701 (Lestaurtinib) in Myelofibrosis (NCT00668421) | Ronald Hoffman | 2008-04-01 |
| Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis (NCT00667277) | Ronald Hoffman | 2008-03-01 |
| Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis (NCT00572065) | Weill Medical College of Cornell University | 2008-02-29 |
| A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis (NCT00631462) | TargeGen | 2008-01-01 |
| Research Tissue Bank (NCT00666549) | Icahn School of Medicine at Mount Sinai | 2007-09-01 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis (NCT00572897) | John Mascarenhas | 2007-08-01 |
| A Safety Study of XL019 in Adults With Myelofibrosis (NCT00522574) | Exelixis | 2007-08-01 |
| Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (NCT00509899) | Incyte Corporation | 2007-06-01 |
| CEP-701 for PH-negative Myelofibrosis (NCT00494585) | M.D. Anderson Cancer Center | 2007-06-01 |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders (NCT00665067) | Icahn School of Medicine at Mount Sinai | 2007-04-01 |
| A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia (NCT00463385) | Celgene | 2007-04-01 |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor (NCT00393380) | The Emmes Company, LLC | 2006-09-01 |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias (NCT00522990) | Astex Pharmaceuticals, Inc. | 2006-09-01 |
| Lenalidomide for Patients With Myelofibrosis (MF) (NCT00352794) | M.D. Anderson Cancer Center | 2006-07-07 |
| Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes (NCT00715247) | University of Utah | 2006-07-01 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia (NCT00360035) | Gemin X | 2006-07-01 |
| A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) (NCT00287261) | Universitaire Ziekenhuizen KU Leuven | 2006-02-01 |
| Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome (NCT00475020) | M.D. Anderson Cancer Center | 2006-01-04 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346) | M.D. Anderson Cancer Center | 2005-11-15 |
| Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload (NCT00235391) | Novartis Pharmaceuticals | 2005-10-01 |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants (NCT00606437) | Duke University | 2005-09-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| Ph II Study of Azacitidine in Myelofibrosis (NCT00569660) | M.D. Anderson Cancer Center | 2005-06-01 |
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (NCT00354120) | Gruppo Italiano Trapianto di Midollo Osseo | 2005-03-01 |
| A Phase II Study of CC-5013 in Myelofibrosis (NCT00087672) | M.D. Anderson Cancer Center | 2004-07-01 |
| RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma (NCT00081874) | M.D. Anderson Cancer Center | 2004-04-01 |
| Genetic Analysis of Gray Platelet Syndrome (NCT00069680) | National Human Genome Research Institute (NHGRI) | 2003-09-29 |
| Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation (NCT00148980) | Hadassah Medical Organization | 2003-04-01 |
| Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients (NCT00599547) | Universitätsklinikum Hamburg-Eppendorf | 2002-11-01 |
| A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) (NCT00136409) | Dana-Farber Cancer Institute | 2002-05-01 |
| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (NCT01499147) | University of Illinois at Chicago | 2000-02-01 |
| Expanded Access to Navitoclax (NCT03592576) | AbbVie | |
| Karyopharm Expanded Access Program for Selinexor (NCT07215832) | Karyopharm Therapeutics Inc | |
| Managed Access Program for Momelotinib in Myelofibrosis (NCT05582083) | GlaxoSmithKline | |
| Individual Patient Compassionate Use of Fedratinib (NCT03723148) | Celgene | |